Cancer drug testing specialist Carcinotech has raised £4.2 million of funding as it looks to build on its traction in the UK and Europe, with US expansion planned later this year.
Set up in 2018 as a spin-out from the University of Edinburgh, Carcinotech's technology enables the manufacture of 3D printed micro-tumours to help accelerate ethical drug screening and the delivery of more effective cancer treatments to market.
The company, which currently employs 10 people, has developed industry partnerships in Europe with firms such as Gothenburg's CELLINK, a specialist in bioprinting solutions. Ishani Malhotra, founder and chief executive of Carcinotech, said the aim now is to replicate such partnerships in North America.
READ MORE: Carcinotech lands seven-figure funding deal to take on cancer
“Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to every individual suffering from cancer to improve their treatment and chance of survival," she said. " Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians, Carcinotech aims to significantly accelerate oncology drug development.”
Eos Advisory was lead investor on the funding deal alongside the Investment Fund for Scotland (IFS), one of a series of nations and regions investment funds set up last year by the British Business Bank. It is the first equity deal from the £150m IFS, which is managed by Maven Capital Partners.
The lead investors are joined by Scottish Enterprise, Old College Capital, and Investing Women Angels along with existing investors Tricapital, SIS Ventures, Gabriel Investment Syndicate, and Alba Equity.
Carcinotech has also recently strengthened its board, chaired by industry veteran Albert Nicholl, and last year launched a scientific advisory board with world renowned oncology leaders.
Director of portfolio Anne Muir said Eos was excited to continue its support of Carcinotech as it enters this next phase of growth which is expected to include new jobs at its based in Edinburgh.
READ MORE: NexaBiome in £10m funding drive to tackle 'silent pandemic'
"Ishani and her team are breaking new ground in oncology, they combine a deep knowledge of the field with technology-driven systems that are set to bring about greater efficiencies in cancer research workflows," she added.
Maven partner David Milroy said: “Carcinotech’s progress over the last 12 months has been impressive and the company is ideally placed to capitalise on the need for more predictive, non-animal models for testing of anti-cancer drugs and the huge opportunity for personalised medicine in cancer treatment.
"Carcinotech’s models are reproducible and provided in a familiar format for high-throughput screening, key requirements for adoption by the pharmaceutical industry for the testing of drug candidates."
READ MORE: Antibody Analytics to expand in major first-time investment
An estimated 19.3 million cancer cases occurred globally in 2020 with a fatality rate of almost 10 million deaths, with breast (11.7%), lung (11.4%), colorectal (10%) and prostate (7.3%) being the most fatal. Although cancer affects millions there are still a limited number of effective therapies available, and those that are available have a high degree of variation from patient to patient.
Kerry Sharp, director of entrepreneurship at Scottish Enterprise, said it is great to see Carcinotech expanding into the US to further develop its potentially life-saving technologies.
"Human health is a key opportunity area for Scotland and we believe that innovative, scaling companies like Carcinotech have an important role to play in transforming our economy," she added.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here